The committee concluded that UroLift is clinically effective, with sustained relief of lower urinary tract symptoms up to 5 years after treatment. It is implanted using a minimally invasive procedure.
WAYNE, Pa.--(BUSINESS WIRE)--NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the publication of ...
Dear Dr. Roach: I'm 79, and for several years, I have been taking finasteride and tamsulosin for benign prostatic hyperplasia. (In the past, I underwent a TURP procedure, which I will never go through ...
WAYNE, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX) (NYSE: TFX), a leading global provider of medical technologies, today announced new research from controlled and real-world ...
DEAR DR. ROACH: I’m 79, and for several years, I have been taking finasteride and tamsulosin for benign prostatic hyperplasia. (In the past, I underwent a TURP procedure, which I will never go through ...
Dear Dr. Roach: I’m 79, and for several years, I have been taking finasteride and tamsulosin for benign prostatic hyperplasia. (In the past, I underwent a TURP procedure, which I will never go through ...
Teleflex Incorporated presented new clinical data at the 2025 American Urological Association Annual Meeting, highlighting the UroLift™ System as a leading minimally invasive treatment for benign ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results